CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...
CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...
CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting ...
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (“Scribe”), a genetic medicines company pioneering next-generation in vivo CRISPR-based medicines designed to be safe, durable, and effective ...
CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing therapy for sickle cell disease. Reimbursement and access for Casgevy now ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results